Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
8E4LAA4357
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
CYTOCHROME P450 2D6
Common Name
English  
HUMAN CYTOCHROME P450 2D6
Common Name
English  
CYTOCHROME P450, FAMILY 2, SUBFAMILY D, POLYPEPTIDE 6
Common Name
English  
CYTOCHROME P 450 2D6
Common Name
English  
CYP2D6
Common Name
English  
Code System Code Type Description Access References
CAS
330597-62-1
Created by admin on Wed Aug 04 03:09:25 EDT 2021 , Edited by admin on Wed Aug 04 03:09:25 EDT 2021
PRIMARY
FDA UNII
8E4LAA4357
Created by admin on Wed Aug 04 03:09:25 EDT 2021 , Edited by admin on Wed Aug 04 03:09:25 EDT 2021
PRIMARY
UNIPROT
P10635
Created by admin on Wed Aug 04 03:09:25 EDT 2021 , Edited by admin on Wed Aug 04 03:09:25 EDT 2021
PRIMARY
Related Record Type Details Access References
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
SELECTIVE
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
LOW
Ki
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
SUBSTRATE
Metabolizing reaction by CYP2D6: N-demethylation Pharmacological action: Phenothiazine antipsychotic
Unidentified
Created by admin on Wed Aug 04 03:34:54 EDT 2021 , Edited by admin on Wed Aug 04 03:34:54 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Lofexidine exposures were approximately 30% greater with co-administration of paroxetine a strong inhibitor of CYP2D6.
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:27 EDT 2021 , Edited by admin on Wed Aug 04 03:09:27 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 06:46:39 EDT 2021 , Edited by admin on Wed Aug 04 06:46:39 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK INHIBITOR
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Metabolizing reaction by CYP2D6: Demethylatio
Created by admin on Wed Aug 04 20:11:01 EDT 2021 , Edited by admin on Wed Aug 04 20:11:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:36 EDT 2021 , Edited by admin on Wed Aug 04 03:09:36 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Strong Inhibitors(2) 5-fold increase in AUC or > 80% decrease in CL
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Metabolizing reaction by CYP2D6: 2-Hydroxylation
Created by admin on Wed Aug 04 21:06:24 EDT 2021 , Edited by admin on Wed Aug 04 21:06:24 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:25 EDT 2021 , Edited by admin on Wed Aug 04 03:09:25 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
N-demethylation of diphenhydramine is mainly catalyzed by CYP2D6 as a high-affinity P450 isozyme at a clinically relevant concentration.
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:31 EDT 2021 , Edited by admin on Wed Aug 04 03:09:31 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
In vitro studies suggest that mephedrone metabolic disposition is regulated by the highly polymorphic isoenzyme of CYP2D6 (Pedersen et al., 2013).
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Abiraterone is an inhibitor of CYP2D6, in vivo. In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK INHIBITION
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:27 EDT 2021 , Edited by admin on Wed Aug 04 03:09:27 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
WEAK INHIBITOR->METABOLIC ENZYME
Mediator Substance Details
none
COMPETITIVE INHIBITOR
Ki
Created by admin on Wed Aug 04 03:09:28 EDT 2021 , Edited by admin on Wed Aug 04 03:09:28 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Interaction with CYP2D6 substrates is not expected to be clinically significant.
IC50
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:36 EDT 2021 , Edited by admin on Wed Aug 04 03:09:36 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:25 EDT 2021 , Edited by admin on Wed Aug 04 03:09:25 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Pharmacological action: Tricyclic antidepressant drug (TCA)
Created by admin on Wed Aug 04 04:20:48 EDT 2021 , Edited by admin on Wed Aug 04 04:20:48 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:26 EDT 2021 , Edited by admin on Wed Aug 04 03:09:26 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:26 EDT 2021 , Edited by admin on Wed Aug 04 03:09:26 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 04:04:07 EDT 2021 , Edited by admin on Wed Aug 04 04:04:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
COMPETITIVE INHIBITOR
Ki
Created by admin on Wed Aug 04 18:36:07 EDT 2021 , Edited by admin on Wed Aug 04 18:36:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
2.1% conversion to M1
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
O-demethylation, mediated by CYP2D6 was greater in extensive metabolizers of CYP2D6 than in poor metabolizers
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
In vitro studies have shown that vilazodone is a moderate inhibitor of CYP2C19 and CYP2D6
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
IN VITRO
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 06:40:26 EDT 2021 , Edited by admin on Wed Aug 04 06:40:26 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Pharmacological action: Tricyclic antidepressant drug (TCA)
Created by admin on Wed Aug 04 17:55:10 EDT 2021 , Edited by admin on Wed Aug 04 17:55:10 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:25 EDT 2021 , Edited by admin on Wed Aug 04 03:09:25 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:27 EDT 2021 , Edited by admin on Wed Aug 04 03:09:27 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MODERATE
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Eliglustat also exhibited time-dependent inhibition (TDI) of CYP2D6.
Ki
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
CYP2C8
IC50
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:28 EDT 2021 , Edited by admin on Wed Aug 04 03:09:28 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
IN-VITRO
Created by admin on Wed Aug 04 13:21:20 EDT 2021 , Edited by admin on Wed Aug 04 13:21:20 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
COMPETITIVE INHIBITOR
IC50
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 11:45:24 EDT 2021 , Edited by admin on Wed Aug 04 11:45:24 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Metabolizing reaction by CYP2D6: O-demethylation
Created by admin on Wed Aug 04 08:31:27 EDT 2021 , Edited by admin on Wed Aug 04 08:31:27 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 11:45:08 EDT 2021 , Edited by admin on Wed Aug 04 11:45:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
TISSUE EXPRESSION -> PARENT
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
REVERSIBLE
Cobimetinib is a reversible inhibitor of CYP3A4 and CYP2D6 in vitro.
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Metabolizing reaction by CYP2D6: N-demethylation
Created by admin on Wed Aug 04 14:11:44 EDT 2021 , Edited by admin on Wed Aug 04 14:11:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
In vitro, lumefantrine significantly inhibits the activity of CYP2D6 at therapeutic plasma concentrations
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:35 EDT 2021 , Edited by admin on Wed Aug 04 03:09:35 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:33 EDT 2021 , Edited by admin on Wed Aug 04 03:09:33 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 16:43:47 EDT 2021 , Edited by admin on Wed Aug 04 16:43:47 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:30 EDT 2021 , Edited by admin on Wed Aug 04 03:09:30 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 03:09:25 EDT 2021 , Edited by admin on Wed Aug 04 03:09:25 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:31 EDT 2021 , Edited by admin on Wed Aug 04 03:09:31 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 03:09:34 EDT 2021 , Edited by admin on Wed Aug 04 03:09:34 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:31 EDT 2021 , Edited by admin on Wed Aug 04 03:09:31 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:09:29 EDT 2021 , Edited by admin on Wed Aug 04 03:09:29 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
COMPETITIVE INHIBITOR
Ki
Created by admin on Wed Aug 04 03:57:17 EDT 2021 , Edited by admin on Wed Aug 04 03:57:17 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 03:09:32 EDT 2021 , Edited by admin on Wed Aug 04 03:09:32 EDT 2021
Structural Modifications
Modification Type Location Site Location Type Residue Modified Extent Modification Name Modification ID Access
Heme binding [1_443] CYS HEME-CYSTEINE (OXIDIZED) G0HAF1JK3T
Name Property Type Amount Referenced Substance Defining Parameters Access References
Molecular Formula CHEMICAL
0
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
0
Created Wed Aug 04 03:09:24 EDT 2021
Created By admin
Last Edited Wed Aug 04 03:09:24 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 Wang, Jun-Sheng, and C. Lindsay DeVane. "Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro." Drug Metabolism and Disposition 31.6 (2003): 742-747. JA PUBLIC_DOMAIN_RELEASE
2 Li, Xiaofeng, et al. "Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly (ADP-ribose) polymerase." Drug metabolism and disposition 39.7 (2011): 1161-1169. JA PUBLIC_DOMAIN_RELEASE
3 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
4 Zhang, Minli, et al. "Identification of 2-aminothiazolobenzazepine metabolites in human, rat, dog, and monkey microsomes by ion-molecule reactions in linear quadrupole ion trap mass spectrometry." Drug Metabolism and Disposition 43.3 (2015): 358-366. JA PUBLIC_DOMAIN_RELEASE
5 Argikar, Upendra A., et al. "Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies." Drug metabolism and disposition 38.8 (2010): 1295-1307. JA PUBLIC_DOMAIN_RELEASE
6 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-144_Ketek_BioPharmr_P3.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
7 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, NOV. 2003, P. 3464?3469 JOURNAL ARTICLE NOMEN
8 Itkonen, Matti K., et al. "Clopidogrel and gemfibrozil strongly inhibit the CYP2C8-dependent formation of 3-hydroxydesloratadine and increase desloratadine exposure in humans." Drug Metabolism and Disposition 47.4 (2019): 377-385. JA PUBLIC_DOMAIN_RELEASE
9 Jones, Barry C., et al. "Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6." Drug metabolism and disposition 26.9 (1998): 875-882. JA PUBLIC_DOMAIN_RELEASE
10 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
11 Generated from relationship on:'OXYMETAZOLINE' SYSTEM
12 FDA_SRS SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
13 Generated from relationship on:'CEVIMELINE' SYSTEM
14 Hvenegaard, Mette G., et al. "Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004." Drug Metabolism and Disposition 40.7 (2012): 1357-1365. JA
15 Generated from relationship on:'IMATINIB' SYSTEM
16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
17 https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021999lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
18 https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
19 Hu, Yiding, and David Kupfer. "Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite." Drug metabolism and disposition 30.9 (2002): 1035-1042. JA PUBLIC_DOMAIN_RELEASE
20 https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
21 Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate Xiangyu Hou, Jialan Zhou, Songda Yu, Lei Zhou, Yifan Zhang, Dafang Zhong and Xiaoyan Chen Drug Metabolism and Disposition September 2018, 46 (9) 1320-1328; DOI: https://doi.org/10.1124/dmd.118.081182 JA PUBLIC_DOMAIN_RELEASE
22 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513 DAILYMED
23 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_ClinPharmR_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
24 Shimizu, Toshiyuki, et al. "Autoinduction of MKC-963 [(R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine] metabolism in healthy volunteers and its retrospective evaluation using primary human hepatocytes and cDNA-expressed enzymes." Drug metabolism and disposition 34.6 (2006): 950-954. JA PUBLIC_DOMAIN_RELEASE
25 Obach, R. Scott. "Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction." Drug metabolism and disposition 29.7 (2001): 1057-1067. JA PUBLIC_DOMAIN_RELEASE
26 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
27 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
28 Cho, Taehyeon M., Randy L. Rose, and Ernest Hodgson. "In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes." Drug metabolism and disposition 34.1 (2006): 176-183. JA PUBLIC_DOMAIN_RELEASE
29 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
30 Mayence, Annie, and Jean Jacques Vanden Eynde. "Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria." Pharmaceuticals 12.3 (2019): 115. JA
31 Projean, Denis, et al. "In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation." Drug Metabolism and Disposition 31.6 (2003): 748-754. JA PUBLIC_DOMAIN_RELEASE
32 HANDBOOK OF DRUG METABOLISM; EDS PAUL PEARSON AND LARRY WIENKERS; INFORMA HEALTHCARE USA, INC.; ISBN-10 1-4200-7647-7; 2009 BOOK NOMEN
33 Kitamura, Ryuichi, et al. "Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68)." Drug metabolism and disposition 36.6 (2008): 1003-1009. JA PUBLIC_DOMAIN_RELEASE
34 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
35 Lin, L. Y., et al. "Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6." Drug Metabolism and Disposition 25.9 (1997): 1059-1064. JA PUBLIC_DOMAIN_RELEASE
36 McClue, Steven J., and Iain Stuart. "Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo." Drug metabolism and disposition 36.3 (2008): 561-570. JA PUBLIC_DOMAIN_RELEASE
37 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
38 Pharmacol Rev 65:578–640, April 2013 JA
39 Cho, Doo-Yeoun, et al. "Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes." Drug Metabolism and Disposition 42.1 (2014): 33-39. JA PUBLIC_DOMAIN_RELEASE
40 Song, Min, et al. "Identification of metabolites of N-(5-benzoyl-2-(4-(2-methoxyphenyl) piperazin-1-yl) thiazol-4-yl) pivalamide including CYP3A4-mediated C-demethylation in human liver microsomes with high-resolution/high-accuracy tandem mass." Drug Metabolism and Disposition 42.8 (2014): 1252-1260. JA PUBLIC_DOMAIN_RELEASE
41 In Vitro Metabolism of Tegaserod in Human Liver and Intestine: Assessment of Drug Interactions Alison E. M. Vickers, Markus Zollinger, Robert Dannecker, Ronald Tynes, Francis Heitz and Volker Fischer Drug Metabolism and Disposition October 2001, 29 (10) 1269-1276; JA PUBLIC_DOMAIN_RELEASE
42 Christensen, Ellen Bech, et al. "Metabolites of [14C]-5-(2-Ethyl-2H-tetrazol-5-yl)-1-methyl-1, 2, 3, 6-tetrahydropyridine in Mice, Rats, Dogs, and Humans." Drug metabolism and disposition 27.11 (1999): 1341-1349. JA PUBLIC_DOMAIN_RELEASE
43 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
44 http://en.wikipedia.org/wiki/CYP2D6 SRS NOMEN
45 https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203975s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
46 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
47 Generated from relationship on:'RUCAPARIB' SYSTEM
48 Pozo, Óscar J., et al. "Mass spectrometric evaluation of mephedrone in vivo human metabolism: identification of phase I and phase II metabolites, including a novel succinyl conjugate." Drug Metabolism and Disposition 43.2 (2015): 248-257. JA PUBLIC_DOMAIN_RELEASE
49 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
50 Subrahmanyam, Vangala, et al. "Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes." Drug Metabolism and Disposition 29.8 (2001): 1146-1155. JA PUBLIC_DOMAIN_RELEASE
51 https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/022004lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
52 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
53 https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
54 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
55 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017854s062lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
56 UNIPROT SRS NOMEN
57 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
58 Wienkers, Larry C., et al. "Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes." Drug metabolism and disposition 27.11 (1999): 1334-1340. JA PUBLIC_DOMAIN_RELEASE
59 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_prntlbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
60 Wienkers, Larry C., and Michael A. Wynalda. "Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine,(S, S)-3-[3-(methylsulfonyl) phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes." Drug metabolism and disposition 30.12 (2002): 1372-1377. JA PUBLIC_DOMAIN_RELEASE
61 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition June 2009, 37 (6) 1152-1156; DOI: https://doi.org/10.1124/dmd.108.026203 JA PUBLIC_DOMAIN_RELEASE
62 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
63 Feng, Meihua Rose, Joseph Loo, and Jonathan Wright. "Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome p450 2D6 extensive metabolizers: Species comparison and allometric scaling." Drug metabolism and disposition 26.10 (1998): 982-988. JA PUBLIC_DOMAIN_RELEASE
64 Patilea-Vrana, Gabriela I., Olena Anoshchenko, and Jashvant D. Unadkat. "Hepatic Enzymes Relevant to the Disposition of (?)-? 9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC." Drug Metabolism and Disposition 47.3 (2019): 249-256. JA PUBLIC_DOMAIN_RELEASE
65 HANDBOOK OF DRUG METABOLISM; EDS PAUL PEARSON AND LARRY WIENKERS; INFORMA HEALTHCARE USA, INC.; ISBN-10 1-4200-7647-7; 2009 BOOK NOMEN
66 Generated from relationship on:'ROLAPITANT' SYSTEM
67 https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
68 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
69 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
70 Sharma, Raman, et al. "Metabolism, excretion, and pharmacokinetics of ((3, 3-difluoropyrrolidin-1-yl)((2S, 4S)-4-(4-(pyrimidin-2-yl) piperazin-1-yl) pyrrolidin-2-yl) methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human." Drug Metabolism and Disposition 40.11 (2012): 2143-2161. JA PUBLIC_DOMAIN_RELEASE
71 Generated from relationship on:'NORTRIPTYLINE' SYSTEM
72 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
73 Imai, Teruko, et al. "In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine." Drug metabolism and disposition 27.8 (1999): 942-946. JA PUBLIC_DOMAIN_RELEASE
74 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
75 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
76 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition November 2008, 36 (11) 2345-2354; DOI: https://doi.org/10.1124/dmd.108.021543 JA PUBLIC_DOMAIN_RELEASE
77 https://www.drugbank.ca/drugs/DB11642 DRUGBANK PUBLIC_DOMAIN_RELEASE
78 http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68 DRUG PRODUCT LABEL NOMEN
79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021602lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
81 Li, Chun, et al. "In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans." Drug Metabolism and Disposition 37.7 (2009): 1378-1394. JA PUBLIC_DOMAIN_RELEASE
82 Takahashi, Ryan H., et al. "Novel mechanism of decyanation of GDC-0425 by cytochrome P450." Drug Metabolism and Disposition 45.5 (2017): 430-440. JA PUBLIC_DOMAIN_RELEASE
83 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
84 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
85 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
86 https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21688_sensipar_lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
87 Walles, Markus, et al. "Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects." Drug Metabolism and Disposition 41.9 (2013): 1626-1641. JA PUBLIC_DOMAIN_RELEASE
88 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022117s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
89 Fischer, Volker, Jean Pierre Baldeck, and F. L. Tse. "Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans." Drug metabolism and disposition 20.4 (1992): 603-607. JA PUBLIC_DOMAIN_RELEASE
90 http://www.aafp.org/afp/2007/0801/p391.html#afp20070801p391-t1 JOURNAL ARTICLE NOMEN
91 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209115Orig1s000Lbl.pdf FDA APPROVED DRUG LABEL NOMEN
92 Nakamura, Katsunori, et al. "Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes." Journal of Pharmacology and Experimental Therapeutics 284.2 (1998): 437-442. JA
93 https://en.wikipedia.org/wiki/Meta-Chlorophenylpiperazine WIKI PUBLIC_DOMAIN_RELEASE
94 Shaffer, Christopher L., et al. "Metabolism and disposition of a selective ?7 nicotinic acetylcholine receptor agonist in humans." Drug metabolism and disposition 35.7 (2007): 1188-1195. JA PUBLIC_DOMAIN_RELEASE
95 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
96 Ding, Juefang, et al. "Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans." Drug Metabolism and Disposition 41.6 (2013): 1195-1210. JA PUBLIC_DOMAIN_RELEASE
97 NDA 205600 PG. 30 NDA PUBLIC REVIEW NOMEN
98 Bakken, Gry Vibeke, et al. "Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro." Drug Metabolism and Disposition 40.9 (2012): 1778-1784. JA PUBLIC_DOMAIN_RELEASE
99 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
100 Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans Lisa J. Christopher, Haizheng Hong, Blisse J. Vakkalagadda, Pamela L. Clemens, Hong Su, Vikram Roongta, Alban Allentoff, Haojun Sun, Kevin Heller, Christopher T. Harbison, Ramaswamy A. Iyer, William G. Humphreys, Tai Wong and Steven Zhang Drug Metabolism and Disposition November 2010, 38 (11) 2049-2059; DOI: https://doi.org/10.1124/dmd.110.034850 JA PUBLIC_DOMAIN_RELEASE
101 Uchiyama, Minoru, et al. "In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor ? agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes." Drug metabolism and disposition 39.7 (2011): 1311-1319. JA PUBLIC_DOMAIN_RELEASE
102 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
103 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
104 Zheng, Nan, et al. "In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes." Drug metabolism and disposition 39.4 (2011): 627-635. JA PUBLIC_DOMAIN_RELEASE
105 STN SRS NOMEN
106 Generated from relationship on:'CARVEDILOL, (-)-' SYSTEM
107 Nucleic Acids Research, 2010, Vol. 38, Database issue D237–D243 doi:10.1093/nar/gkp970 JA
108 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 03:09:22 EDT 2021
109 Generated from relationship on:'FLUVOXAMINE' SYSTEM
110 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
111 Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction Aarti Sawant-Basak, R. Scott Obach, Angela Doran, Peter Lockwood, Klaas Schildknegt, Hongying Gao, Jessica Mancuso, Susanna Tse and Thomas A. Comery Drug Metabolism and Disposition July 2018, 46 (7) 934-942; DOI: https://doi.org/10.1124/dmd.118.080457 JA PUBLIC_DOMAIN_RELEASE
112 Kassahun, Kelem, et al. "Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor." Drug metabolism and disposition 29.6 (2001): 813-820. JA PUBLIC_DOMAIN_RELEASE
113 Gantenbein, Manon, et al. "Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A." Drug metabolism and disposition 28.4 (2000): 383-385. JA PUBLIC_DOMAIN_RELEASE
114 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
115 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
116 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
117 SRS import [8E4LAA4357] SRS NOMEN Fri Apr 28 15:05:43 EDT 2017
118 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
119 Fischer, V., et al. "The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron." Drug metabolism and disposition 22.2 (1994): 269-274. JA PUBLIC_DOMAIN_RELEASE
120 Cho, Doo-Yeoun, et al. "Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes." Drug Metabolism and Disposition 42.1 (2014): 33-39. JA PUBLIC_DOMAIN_RELEASE
121 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
122 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
123 https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21436_Abilify_lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
124 Peters, Frank T., et al. "Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4?-Methyl-?-pyrrolidinobutyrophenone." Drug metabolism and disposition 36.1 (2008): 163-168. JA PUBLIC_DOMAIN_RELEASE
125 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021882_s000_Exjade_BioPharmr.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
126 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
127 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
128 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
129 Generated from relationship on:'CARVEDILOL, (+)-' SYSTEM
130 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
131 BIOL. PHARM. BULL. 24 (11) 1263?1266 (2001) JOURNAL ARTICLE NOMEN
132 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
133 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204760Orig1s000ClinPharm.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
134 Vevelstad, Merete, et al. "Studies on para-methoxymethamphetamine (PMMA) metabolite pattern and influence of CYP2D6 genetics in human liver microsomes and authentic samples from fatal PMMA intoxications." Drug Metabolism and Disposition 45.12 (2017): 1326-1335. JA PUBLIC_DOMAIN_RELEASE
135 Pratt-Hyatt, Matthew, et al. "Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide." Drug metabolism and disposition 38.11 (2010): 2075-2082. JA PUBLIC_DOMAIN_RELEASE
136 GLEEVEC (IMATINIB MESYLATE) TABLET \\n[NOVARTIS PHARMACEUTICALS CORPORATION] FDA APPROVED DRUG LABEL NOMEN
137 Voorman, Richard L., et al. "Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A." Drug metabolism and disposition 26.7 (1998): 631-639. JA PUBLIC_DOMAIN_RELEASE
138 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
139 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
140 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#classInhibit FDA GUIDANCE NOMEN
141 Prakash, Chandra, et al. "Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers." Drug metabolism and disposition 26.5 (1998): 448-456. JA PUBLIC_DOMAIN_RELEASE
142 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
143 Kotsuma, Masakatsu, et al. "Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans." Drug metabolism and disposition 36.8 (2008): 1505-1511. JA PUBLIC_DOMAIN_RELEASE
144 Argikar, Upendra A., et al. "Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies." Drug metabolism and disposition 38.8 (2010): 1295-1307. JA PUBLIC_DOMAIN_RELEASE
145 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
146 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
147 Talakad, Jyothi C., et al. "Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4." Drug metabolism and disposition 39.3 (2011): 539-550. JA PUBLIC_DOMAIN_RELEASE
148 NOLVADEX (TAMOXIFEN CITRATE) TABLET \\n [ASTRAZENECA PHARMACEUTICALS LP] FDA APPROVED DRUG LABEL NOMEN
149 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-565_Elestat_BioPharmr.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
150 Akutsu, Tomoko, et al. "Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation." Drug metabolism and disposition 35.1 (2007): 72-78. JA PUBLIC_DOMAIN_RELEASE
151 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
152 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
153 https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21427lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
154 HANDBOOK OF DRUG METABOLISM; EDS PAUL PEARSON AND LARRY WIENKERS; INFORMA HEALTHCARE USA, INC.; ISBN-10 1-4200-7647-7; 2009 BOOK NOMEN
155 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000ClinpharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
156 Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor Faraz Kazmi, Phyllis Yerino, Joanna E. Barbara and Andrew Parkinson Drug Metabolism and Disposition September 2015, 43 (9) 1294-1302; DOI: https://doi.org/10.1124/dmd.115.065011 JA PUBLIC_DOMAIN_RELEASE
157 Niwa, Toshiro, et al. "Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A." Drug metabolism and disposition 28.9 (2000): 1128-1134. JA PUBLIC_DOMAIN_RELEASE
158 Jones, Barry C., et al. "Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6." Drug metabolism and disposition 26.9 (1998): 875-882. JA PUBLIC_DOMAIN_RELEASE
159 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-395.pdf_Spiriva_BioPharmr_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
160 Postlind, Hans, et al. "Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes." Drug metabolism and disposition 26.4 (1998): 289-293. JA PUBLIC_DOMAIN_RELEASE
161 HANDBOOK OF DRUG METABOLISM; EDS PAUL PEARSON AND LARRY WIENKERS; INFORMA HEALTHCARE USA, INC.; ISBN-10 1-4200-7647-7; 2009 BOOK NOMEN
162 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
163 STN STN (SCIFINDER)
164 Wen, Bo, et al. "Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine." Drug metabolism and disposition 36.5 (2008): 841-850. JA PUBLIC_DOMAIN_RELEASE
165 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
166 Pedersen, Anders Just, Trine Hedebrink Petersen, and Kristian Linnet. "In vitro metabolism and pharmacokinetic studies on methylone." Drug Metabolism and Disposition 41.6 (2013): 1247-1255. JA PUBLIC_DOMAIN_RELEASE
167 Generated from relationship on:'CHLORPROMAZINE' SYSTEM
168 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
169 Peyronneau, Marie-Anne, et al. "Metabolism and quantification of [18F] DPA-714, a new TSPO positron emission tomography radioligand." Drug Metabolism and Disposition 41.1 (2013): 122-131. JA PUBLIC_DOMAIN_RELEASE